Nitrated Subunit Vaccine Platform: Engineering Intrinsic Immunogenicity into Pathogen Antigens
This technology makes safe protein-based vaccines much stronger by attaching a small chemical trigger directly onto pathogen proteins, helping the immune system recognize and fight infections without changing the protein's natural shape. As a result, vaccine developers can create more effective, needle-free mucosal and systemic vaccines using scalable bacterial manufacturing while reducing the need for extra chemical boosters.
Background
Subunit vaccines are modern, targeted immunizations that use only specific, purified protein fragments from a germ rather than the entire live or killed pathogen. Because they omit the whole pathogen, subunit formulations offer superior stability, high safety profiles, and fewer adverse reactions than traditional whole-cell vaccines. However, when isolated from their natural structural context, these recombinant protein antigens often suffer from inherently poor immunogenicity and fail to stimulate robust innate, mucosal, and systemic immune cascades. To compensate for weak immune recognition, current subunit protocols rely heavily on high loads of external adjuvants or complex delivery vehicles—approaches that complicate manufacturing, increase side effects, and frequently yield suboptimal protection against critical pathogens like Shigella flexneri.
Technology
University of Delaware Researchers have developed this vaccine platform that overcomes the poor immunogenicity of subunit targets by engineering intrinsic immunogenicity directly into foreign pathogen proteins. Utilizing engineered Escherichia coli and amber stop-codon suppression, the technology site-specifically substitutes native aromatic amino acids with nonstandard nitrated residues, notably para-nitro-L-phenylalanine (pN-Phe). Validated using a truncated invasion plasmid antigen D (IpaD) from Shigella flexneri, this modification introduces a minimal steric footprint that preserves the antigen’s native folding and core conformational epitopes while downstream chromatographic processing ensures low endotoxin levels. In murine models, mucosal delivery of the nitrated antigen elicited significantly higher systemic IgG and mucosal IgA titers, balanced Th1/Th2 responses, and strong cross-reactivity against native pathogen proteins by focusing B-cell recognition and boosting innate immune activation.
Benefits
- Potent Multi-Layered Immunity: Significantly enhances innate, mucosal (IgA), and systemic (IgG) immune responses alongside balanced Th1/Th2 helper T cell activation.
- Preserved Structural Integrity: Introduces a minimal steric footprint that maintains native secondary folding and conformational epitopes while eliminating invasive virulence.
- Focused Epitope Recognition: Directs and intensifies B-cell recognition toward specific target epitopes while generating strong antibody cross-reactivity against wild-type pathogens.
- Adjuvant-Sparing Potential: Builds intrinsic immunogenicity directly into the polypeptide backbone, reducing formulation complexity and reliance on external adjuvants.
- Scalable & Generalizable Platform: Leverages standard E. coli expression and chromatographic purification to rapidly adapt across diverse bacterial, viral, and fungal targets.
Applications
- Shigellosis Preventive Subunit Vaccines: Targeted prophylactic formulations utilizing nitrated IpaD antigens to combat enteric Shigella flexneri infections.
- Subunit Vaccine Immunogenicity Enhancement: Upgrading weak recombinant protein candidates across bacterial, viral, and fungal infectious disease pipelines.
- Mucosal Vaccine Formulation Development: Engineering needle-free, mucosal-delivered antigens capable of generating robust localized IgA and systemic protection.
- Adjuvant-Sparing Antigen Engineering: Developing self-adjuvanting protein backbones to lower reactogenicity and simplify vaccine manufacturing workflows.
- Custom Recombinant Antigen Design Services: Partnering with biopharmaceutical developers to optimize epitope targeting and immune potency for proprietary vaccine targets.
Additional info
This platform comprises antigenic recombinant polypeptides and vaccine compositions featuring site-specific substitution of native aromatic residues with para-nitro-L-phenylalanine (pN-Phe). Expressed through orthogonal amber stop-codon suppression in engineered Escherichia coli, these structural variants—such as truncated Shigella flexneri IpaD (Y90pN-Phe)—preserve native folding while boosting immunogenicity. Administration elicits elevated cross-reactive systemic IgG, mucosal IgA, neutrophil recruitment, and upregulation of CD80/CD86 on antigen-presenting cells.